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bjectives We sought to compare patient-oriented outcomes related to target vessel or nontarget
essel events for sirolimus-eluting stents (SES) versus bare-metal stents.
ackground SES signiﬁcantly reduce restenosis but the inﬂuence of reduced restenosis on overall
atient-oriented outcome has not been reported.
ethods The study population included 1,057 patients randomized in the SIRIUS (Sirolimus-Eluting
tent in De Novo Native Coronary Lesions) study and followed clinically for 5 years. The primary end
oint was a composite of all-cause mortality, any myocardial infarction, or any repeat revasculariza-
ion. In secondary analyses, myocardial infarction and repeat revascularization events attributed to
he target vessel or a nontarget vessel were compared by stent type.
esults Patients with an SES were more likely to be free from the primary composite end point at
years (60.4% vs. 47.8%, p  0.001) chieﬂy due to a sustained reduction in target lesion revascular-
zation for SES (cumulative incidence: 12.5% vs. 28.8%, p  0.001). There was no difference in the
umulative incidence of myocardial infarction or revascularization attributed to remote segments of
he target vessel. Events attributed to the nontarget vessel were frequent and not different for SES
ersus bare-metal stents (25.7% vs. 25.8%).
onclusions The beneﬁt of SES over bare-metal stents for reduced target lesion revasculariza-
ion is maintained for 5 years. Remote coronary segments of the target vessel and nontarget
essel remain an important cause of future adverse events despite sustained restenosis
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499rug-eluting stents (DES) have been shown to significantly
educe restenosis compared with bare-metal stents (BMS)
1–3). Despite the benefit in restenosis, there remains a
oncern for a small, but clinically significant increased risk
or late and very late stent thrombosis (4). This balance in
vents of restenosis and stent thrombosis related to the
arget lesion has contributed to an overall risk for death or
yocardial infarction (MI) that is not different between
MS and DES (5). Although the influence of safety and
ffectiveness outcomes related to the target lesion is impor-
ant for assessment of the biologic effect of the device, a
See page 513
atient-oriented composite that includes all-cause mortality,
ny MI, and any revascularization, has been suggested as a
ore important measure of device influence on clinical out-
ome (6,7). We have reported previously that during 5-year
ollow-up of BMS clinical trial patients, outcomes after the
rst year are determined mostly by events attributable to
isease progression unrelated to the target lesion (8). It has
een questioned if restenosis itself may have an impact on these
istant outcomes, due to increased surveillance for recurrent
ymptoms or adverse effects of repeat revascularization proce-
ures. Furthermore, it has also been suggested that sirolimus-
luting stents (SES) may result in adverse events related to
ndothelial dysfunction remote from the stented coronary
egments (9,10).
We hypothesized that the events related to disease
rogression would be frequent but similar in BMS and SES
atients. We sought to evaluate the affect of disease pro-
ression at sites remote from the target lesion on patient-
riented outcome for SES and BMS during 5-year
ollow-up of the SIRIUS (Sirolimus-Eluting Stent in De
ovo Native Coronary Lesions) trial.
ethods
tudy design. The study population included patients ran-
omized in the SIRIUS study. The design of SIRIUS has
een previously reported (1). After approval of the device by
he U.S. Food and Drug Administration, study patients
ere to be followed for 5 years. Treatment assignment
emained masked during the follow-up. Patients were que-
ied by telephone interview, and in the case of potential
linical events, source medical documents were retrieved and
eviewed.
For this study, all rehospitalizations and suspected clinical
nd points were reviewed and adjudicated according to the
riteria recommended by the Academic Research Consor-
ium for the patient-oriented composite, defined as all-cause
ortality, any MI, and any repeat revascularization (6).
vents were classified further according to attribution to apecific coronary segment based on the CASS (Coronary frtery Surgery Study) trial classification or to a coronary
essel if the specific segment could not be determined.
ndependent central core laboratory analyses were available
or electrocardiography and coronary angiography at base-
ine and for suspected clinical events.
nd point deﬁnitions and classiﬁcation. The primary end
oint was the patient-oriented composite. Deaths were
urther categorized as cardiac unless a clear noncardiac cause
as identified. Deaths could generally not be assigned to a
pecific coronary segment or vessel and were included as
oth target vessel and nontarget vessel events. Academic
esearch Consortium and Global Task Force recommen-
ations (6,11) were used to define MI. Periprocedural MI
as defined as creatine kinase-myocardial band 3 times
he upper reference limit if after percutaneous coronary
ntervention or creatine kinase-myocardial band 5 times
he upper reference limit after coronary artery bypass sur-
ery, and spontaneous MI was defined as any signs or
ymptoms of acute myocardial ischemia with troponin or
reatine kinase-myocardial band above the upper reference
imit. Myocardial infarction was attributed to a CASS
egment according to angiogra-
hy if available or a specific ves-
el territory based on serial elec-
rocardiograms at baseline and
he time of the event. Repeat
evascularization procedures were
ttributed to 1 or more CASS
egments based on review of
oronary angiography by the
ore laboratory. The target le-
ion was defined as the CASS
egment containing the origi-
ally stented lesion. The target vessel was defined as the
arget lesion or any other CASS segment within the same
picardial vessel or 1 of its side branches. Segments of the
arget vessel not including the target lesion were termed
arget vessel remote segments. A nontarget vessel was
efined as either of the epicardial coronary arteries not
ncluding the target lesion. For MI and repeat revascular-
zation, events were attributed to the target vessel unless
here was clear evidence of nontarget vessel involvement.
Secondary end points included a target vessel compos-
te, defined as any cardiac death, MI involving the target
essel territory, or target vessel revascularization, and a
ontarget vessel composite, defined as any cardiac death,
I clearly attributable to a nontarget vessel, or nontarget
essel revascularization
tatistical analysis. The comparison of baseline characteris-
ics between patients experiencing the primary end point
nd those who remained free of an end point event was
erformed using chi-square or Fisher exact test for dichot-
mous outcomes and Student t or Wilcoxon rank sum test
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MI  myocardial infarction
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationor continuous outcomes. Event-free survival was estimated
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500y Kaplan-Meier method and the comparison of survival
urves between groups was performed using the log-rank
est. Cox proportional hazards regression was used to
valuate for the association of baseline variables with the
rimary end point after confirmation of proportional hazard
ssumptions.
esults
tudy patients and follow-up compliance. Of 1,058 patients
nrolled in the SIRIUS trial, 1 patient with stenting
nvolving a vein graft was excluded from this analysis.
omplete 5-year follow-up for the mortality end point was
vailable for 456 of 533 (86%) DES and 446 of 524 (85%)
MS patients. The mean follow-up duration was 1,689 
39 days for DES and 1,704  296 days for BMS groups.
linical outcomes. Patients who experienced the primary
nd point were less likely to receive a SES and had a higher
requency of diabetes, prior MI, or prior bypass surgery
Table 1). The cumulative incidences for the primary end
oint and each of the components are shown in Table 2, and
reedom from the primary end point over the 5-year
Table 1. Baseline Patient Characteristics
No Primary End P
Sirolimus-eluting stent, % 56.3
Age, mean  SD, yrs 62.50 
Male, % 69.8
Prior myocardial infarction, % 26.0
Diabetes, % 23.2
Hypertension, % 67.0
Coronary artery bypass surgery, % 7.7
Hyperlipidemia, % 73.2
Left ventricular ejection fraction, mean  SD, n 56 
Table 2. 5-Year Outcomes of SES Versus BMS
Event
SES (n  533) BMS (n  524)
p
Value†n
Cumulative
Incidence* n
Cumulative
Incidence*
Patient-oriented composite 205 39.6 269 52.8 0.001
Death, all causes 44 8.5 44 8.7 0.967
Cardiac death 20 4.0 19 3.7 0.889
Noncardiac death 24 4.5 25 5.0 0.858
Myocardial infarction 65 12.5 71 13.8 0.521
Target vessel 47 8.5 59 11.3 0.197
Nontarget vessel 18 3.6 12 2.5 0.284
Revascularization 165 32.3 230 45.0 0.001
Target lesion 64 12.5 148 28.8 0.001
Target vessel remote 59 11.7 78 15.0 0.069
Nontarget vessel 113 22.3 115 22.9 0.801
*Cumulative incidence (%) based on Kaplan-Meier estimate. †Comparison by log-rank.PBMS bare-metal stent(s); SES sirolimus-eluting stent(s).ollow-up is shown in Figure 1A. At 1 year, there was a
ignificantly lower risk for the primary end point for the
ES group and this difference was maintained at 5 years.
his difference was driven by reduced target lesion revascu-
arization (TLR) without a difference in target vessel revas-
ularization remote from the target lesion, death, MI, or
ontarget vessel revascularization throughout the 5-year
ollow-up. The survival curves for the secondary end point
f target vessel outcome also demonstrated a significant
ifference by 1 year and were then also essentially parallel
Fig. 1B). The survival curves for the secondary end point of
ontarget vessel outcomes overlapped throughout, demon-
trating an annual hazard rate of approximately 5% to 6%
er year for each stent type (Fig. 1C).
The relative annual hazard rates for TLR, remote
arget vessel MI or revascularization, and nontarget vessel
I or revascularization are depicted for BMS and SES in
igure 2.
redictors of the primary end point. The independent pre-
ictors of the primary end point are shown in Table 3.
ssignment to SES remained as a significant protective
actor for the patient-oriented composite end point during
-year follow-up. Diabetes was a significant predictor, but
he interaction of diabetes and stent type was not.
iscussion
uring 5 years of clinical follow-up, patients randomized to
eceive a SES at the time of the index procedure were
ignificantly less likely to suffer the patient-oriented com-
osite outcome. This benefit proved to be entirely due to a
eduction in TLR that was present after 1 year and
ustained thereafter. All-cause mortality, cardiac mortality,
nd MI were all similar for the SES and BMS groups. A
arge proportion of events were attributed to a nontarget
essel, with over 25% of patients in each group sustaining a
ontarget vessel event.
A patient-oriented composite has been proposed as the
est reflection of overall benefit or harm when comparing
lternative treatments such as DES versus BMS (6,7).
 583) Primary End Point (n  474) p Value
43.2 0.001
61.92  11.05 0.399
72.8 0.306
36.0 0.001
30.2 0.011
68.6 0.596
11.6 0.035
74.2 0.725
56  10 0.965oint (n
11.08revious studies that have focused only on target lesion or
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501arget vessel events fail to assess whether a reduction in
estenosis has a significant impact on overall outcome,
hich is influenced not only by the balance of safety and
ffectiveness of the restenosis preventive therapy itself but
lso progression of disease at other sites. The large and
ustained reduction in TLR for SES in the SIRIUS trial
onfirms previous reports (12–14) and was sufficient to
esult in a significant improvement in the patient-oriented
omposite.
Whereas the patient-oriented composite is a better mea-
ure of net risk and benefit, it is still limited by combining
Figure 1. Kaplan Meier 5-Year Event-Free Survival Comparing SES Versus B
(A) Patient-oriented composite of all-cause mortality, any myocardial infarction
ing target vessel territory (TV MI), or target vessel revascularization (TVR). (C) F
nontarget vessel revascularization (NTVR). Solid lines indicate sirolimus-elutingvents of unequal severity, such as death and revasculariza- aion. In that regard, it is important to note that our study
onfirms a prior report of a pooled analysis of 4-year
utcomes by Stone et al. (5) that showed no significant
ifference between SES and BMS in all-cause mortality,
ardiac mortality, or MI.
There has been concern that SES may result in increased
isk for events remote from the target lesion due to reports
f endothelial dysfunction at distant sites (9). Progression of
isease requiring repeat revascularization in segments of the
arget vessel remote from the target lesion actually tended to
e lower for SES than BMS, possibly reflecting imperfect
or any repeat revascularization. (B) Freedom from cardiac death, MI involv-
m from cardiac death, MI involving nontarget vessel territory (NTV MI) or
s (SES) and dashed lines indicate bare-metal stents (BMS).MS
(MI),
reedossessment of restenosis, but not indicative of more rampant
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502isease progression at sites distal or proximal from the SES
tent. Myocardial infarction attributed to the target vessel
as also not different between SES and BMS. The result of
hese findings was a significant benefit for SES in overall
vents attributed to the target vessel.
Although a sustained reduction in TLR resulting in a net
enefit in patient outcome for SES is encouraging, the
mpact of disease progression in nontarget vessels on the
atient-oriented composite in both SES and BMS patients
emains a concern. It has been reported previously that
isease progression, rather than restenosis, after BMS is the
ost important cause of subsequent events (8,15). Indeed in
he current study, events attributed to the nontarget vessel
ere the most frequent cause of adverse outcome in the SES
roup during the 5-year follow-up period. This is similar to
previous report among diabetic patients, in which over
0% of repeat revascularization procedures in SES patients
uring 2-year follow-up did not involve the target lesion
16). The annual hazard for target vessel remote and
ontarget vessel events was similar among the SES and
MS patients and to prior reports from BMS studies. It has
een suggested that restenosis itself may have contributed to
he high rates of target vessel and nontarget vessel events in
Figure 2. Annual Hazards of TLR, Target Vessel Events Excluding TLR, and
(A) Bare-metal stent cohort. (B) Sirolimus-eluting stent cohort. MI  myocardia
revascularization.
Table 3. Predictors of the Primary End Point Based on Cox Proportional
Hazard Model
Variable
Hazard
Ratio
95%
Confidence
Interval p Value
Sirolimus-eluting stent 0.66 0.55–0.79 0.001
History of myocardial infarction 1.36 1.13–1.65 0.002
History of diabetes 1.29 1.06–1.57 0.012
Prior coronary artery bypass graft surgery 1.44 1.08–1.92 0.012
Pre-procedure reference vessel diameter, mm 0.77 0.63–0.94 0.001lPre-procedure lesion length, mm 1.03 1.01–1.04 0.001hese earlier BMS studies, due to recurrent ischemia and
ngoing surveillance. The similar risk for these events in the
ES and BMS groups, despite clear differences in restenosis
vents, suggests the occurrence or prevention of restenosis
ad no major impact.
Our study is the first to report results from a randomized,
ouble-blinded controlled trial regarding progression of
oronary disease in coronary segments remote from the
arget lesion. There are important implications of these
ndings for future development and clinical application of
ES. As applied in the SIRIUS trial, the benefit of SES
as limited to a reduction in TLR that was most marked
uring the first year. The ongoing risks of events unrelated
o restenosis reduced the relative benefit of this protection
rom 50% after 1 year to 25% at 5 years. Disease
rogression may result in lesser benefit for a DES strategy
hen the primary end point is determined by clinical
utcomes other than restenosis. On the other hand, im-
rovements in DES technology that maintain or increase
he restenosis benefit while reducing the safety risk to a level
ignificantly below the inherent risk associated with pro-
ression of subclinical coronary artery disease may provide
or a pre-emptive therapeutic strategy that can markedly
educe overall coronary events. Whether these lesions can be
dentified prospectively by measures of plaque vulnerability
r accelerated progression and whether local or regional
herapy will offer any advantage over systemic medical
herapy will require randomized trial evaluation (17). Fi-
ally, the findings of our study have implications for the
alidity of attributing late unexplained events to stent
hrombosis or other stent-related complications.
tudy limitations. Our study has several limitations. Be-
ause routine biomarker assays were not mandated during
epeat hospitalizations or subsequent revascularization, it is
arget Vessel Events
rction; PCI  percutaneous coronary intervention; TLR  target lesionNont
l Infaikely that spontaneous MI may have been underestimated.
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503e also did not record medication use during the follow-up
eriod, so the impact of longer term clopidogrel therapy
eyond the protocol-mandated 3 months or of statins on
ate events cannot be assessed. Finally, our results are
estricted to a clinical trial population undergoing coronary
tenting according to a specified protocol. Given the gen-
rally accepted low risk of these patients, the findings of a
igh risk for disease progression may have even greater
elevance. Moreover, because the protocol specified routine
ngiographic follow-up with its documented inherent bias,
e cannot exclude an exaggeration of the impact of TLR
elative to nontarget vessel events.
onclusions
ES were associated with a marked reduction in a patient-
riented composite outcome as defined by the Academic
esearch Consortium, including all-cause mortality, any
I, or any repeat revascularization, during the 5 years after
tenting. This benefit was due to a significant reduction in
LR during the first year that was sustained for 5 years.
vents attributed to the remote segments of the target vessel
nd nontarget vessels occurred frequently and were nearly
dentical between SES and BMS. Remote coronary seg-
ents remain an important cause of future adverse events
nd limit the relative benefit of DES during longer term
ollow-up.
eprint requests and correspondence: Dr. Donald E. Cutlip,
eth Israel Deaconess Medical Center, 330 Brookline Avenue,
oston, Massachusetts 02215. E-mail: dcutlip@bidmc.
arvard.edu.
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